中文
Press Release
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
Aug 23, 2022
Mabwell's Innovative Drug 6MW3511 Injection is Approved for Clinical Trial

➞
Aug 17, 2022
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for JUNMAIKANG® (Adalimumab)

➞
Jul 29, 2022
Mabwell’s anti-Nectin-4 ADC drug received FDA’s IND Approval

➞
Jul 27, 2022
Mabwell Included in the List of 2021 New Shanghai Technology Innovation Center

➞
Jul 14, 2022
Mabwell and PKUCare Luzhong Hospital Established a Strategic Alliance

➞
Jun 17, 2022
The IND Application for 6MW3511 Injection - An Innovative Drug from Mabwell is Accepted by NMPA

➞
Mar 28, 2022
Achievements in Scientific Research | Mabwell Published ADE Mechanism of SARS-CoV-2 Neutralizing Antibodies in Communications Biology

➞
Mar 03, 2022
Good News! Mabwell's First Drug Adalimumab Approved for Marketing

➞
Feb 17, 2022
The IND Application of Mabwell Innovative Drug 8MW2311 for Injection was Accepted by NMPA

➞
Feb 14, 2022
Through New Chapter | Industry Big Names Discuss the Rheumatism Immunity Disease Webinar

➞
Previous1 2 3 Next